MORE►
Animal Capital
Dr. Beth Shapiro and Colossal Co-Founder and CEO Ben Lamm with a stuffed dodo. [Photo: Colossal]
Texas-Based Colossal Achieves Unicorn Status With $150M Series B Raise, Plans To ‘De-Extinct’ the Dodo Bird
by David Seeley | Jan 31, 2023
Colossal says its efforts could help boost "the U.S. high-tech advantage." Its gene editing technologies "will make waves across sectors—in agriculture with new biofuels and preserving biodiversity, as well as in human health through improved gene therapy and vaccine development," the company said.
by Quincy Preston and David Seeley |
Mar 9, 2022
Colossal launched last September with a plan to "de-extinct" the woolly mammoth by using CRISPR genetic engineering to create a mammoth-elephant hybrid.
With a total raise of $75 million to date, the startup aims to
have its first set of mammoth-elephant hybrid calves "in 4 to 6 years," co-founder and CEO Ben Lamm told us. But Colossal's goals extend much further—with the potential "to advance human health, enhance food production, reduce environmental impact, and optimize animal health and welfare."
MORE►
